title: Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.
abstract: Renal involvement is an unusual but significant Behcet´s disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 is a pro-inflammatory cytokine with an important role in AA amyloidosis development. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. We report on a patient diagnosed with BD who developed nephrotic syndrome caused by renal AA amyloidosis with an excellent response to TCZ therapy.
authors.affiliation: Nephrology Section, Hospital de Elche, Elche, Spain. dolypa@hotmail.com
authors.forename: M D
authors.initials: MD
authors.lastname: Redondo-Pachón
authors.forename: R
authors.initials: R
authors.lastname: Enríquez
authors.forename: A E
authors.initials: AE
authors.lastname: Sirvent
authors.forename: E
authors.initials: E
authors.lastname: Andrada
authors.forename: R
authors.initials: R
authors.lastname: Noguera-Pons
authors.forename: I
authors.initials: I
authors.lastname: Millán
authors.forename: F
authors.initials: F
authors.lastname: Amorós
mesh_terms: D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology*; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab